Compare AbCellera Biologics Inc (ABCL) vs Intel Corp (INTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Intel Corp — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Intel Corp trades at $107.6 (market cap $554.82B). The key difference: Intel Corp is far larger — about 236.1× AbCellera Biologics Inc's market cap, and Intel Corp pays a 2.24% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | INTC | |
|---|---|---|
Market Cap | $2.35B | $554.82B |
Sector | Health | Technology |
52-Week High | $8.12 | $140.94 |
52-Week Low | $2.78 | $19.31 |
Enterprise Value | $1.99B | $567.06B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Intel (INTC) trades at $110.39, down 8.28% amid a sector-wide chip selloff triggered by Samsung's earnings reaction. Despite beating EPS estimates for three consecutive quarters, the stock shows weak profitability with a negative net income margin and ROE. Technical indicators are neutral, with support at $114 and resistance at $124. Cash flow improved in 2025, but revenue remains flat year-over-year, highlighting growth challenges.
The outlook is mixed: analyst consensus is a 'Hold' with a $97.74 price target below current levels, reflecting skepticism about near-term execution. Risks include intense competition and cyclical semiconductor demand, but potential upside exists if foundry partnerships and AI-driven CPU demand materialize as projected by bullish analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
